BRWA
NAGE

B. Riley Wealth Advisors’s Niagen Bioscience NAGE Stock Holding History

B. Riley Wealth Advisors’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-14,000
Closed -$59K – 737
2018
Q1 		$59K Buy
+14,000
New +$73.3K 0.01% 649

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

B. Riley Wealth Advisors's NAGE Position: Q2 2018 in Review

B. Riley Wealth Advisors sold out of Niagen Bioscience (NAGE) in Q2 2018, closing a stake of 14,000 shares — an estimated $59K sold.

B. Riley Wealth Advisors first reported a position in NAGE in Q1 2018 and held it in 1 quarter. The position peaked at $59K in Q1 2018. 64 funds tracked by Wall St. Rank hold NAGE as of Q2 2018.

  • B. Riley Wealth Advisors reported no remaining Niagen Bioscience position as of Q2 2018 after selling out during the quarter.
  • B. Riley Wealth Advisors sold 14,000 Niagen Bioscience shares in Q2 2018, an estimated $59K.
  • B. Riley Wealth Advisors first reported a position in Niagen Bioscience in Q1 2018 and held it in 1 quarter.
  • B. Riley Wealth Advisors's Niagen Bioscience position peaked at $59K in Q1 2018.
  • 64 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2018.

Based on B. Riley Wealth Advisors's 13F filing for Q2 2018, filed 5 Oct 2018.